Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

This study is testing a new drug called EP31670 that blocks two proteins — BET and CBP/p300 — that help cancer cells grow. It is being tested in patients with certain advanced cancers including prostate cancer, a rare cancer called NUT carcinoma, a blood cancer called chronic myelomonocytic leukemia (CMML), and a bone marrow disease called myelofibrosis (MF). **You may be eligible if...** - You have advanced castration-resistant prostate cancer that has progressed on hormone therapy and chemotherapy - You have unresectable NUT carcinoma - You have CMML that hasn't responded to standard treatment - You have intermediate or high-risk myelofibrosis that hasn't responded adequately to a JAK inhibitor - You are in generally good health (able to carry out daily activities) - Your kidney and liver function are adequate **You may NOT be eligible if...** - You have active, growing brain metastases - You have a heart rhythm problem (prolonged QT interval) - You have uncontrolled infections or serious heart conditions - You are pregnant or breastfeeding - You have untreated hepatitis B, hepatitis C, or HIV with detectable virus Talk to your doctor to see if this trial is right for you.